Affy to Miss Q2 Guidance Due to Delayed Instrument Purchases, Declining Expression Sales

Affymetrix expects to report second-quarter revenues of $71 million to $72 million, as much as 13 percent below guidance of $80 million to $82 million the company provided when it released its first-quarter results in April.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.